# Eli Lilly and Company > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Eli Lilly and Company). ## Overview Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products, with a portfolio anchored by diabetes, obesity, oncology, immunology, and neuroscience medicines. The company sells medicines in about 90 countries and combines traditional physician-directed promotion with direct-to-patient channels such as LillyDirect in certain markets. ## Products & services • Diabetes medicines, including Mounjaro and other incretin therapies • Obesity treatment, including Zepbound • Oncology medicines, including Verzenio • Immunology and neuroscience medicines • LillyDirect direct-to-patient access platform • Global commercialization, distribution, and patient-support services - **Diabetes and obesity medicines** (65%) — Incretin-based therapies and related products used to treat type 2 diabetes and obesity. - **Oncology medicines** (15%) — Cancer therapies, including branded treatments used in breast and other cancers. - **Immunology and neuroscience medicines** (10%) — Specialty medicines for immune and central nervous system conditions. - **Other human pharmaceutical products** (8%) — Legacy and smaller products across additional therapeutic areas and geographies. - **Digital access and support services** (2%) — LillyDirect and related patient access, adherence, and care-navigation services. - Diabetes medicines, including Mounjaro and related therapies - Obesity treatment, including Zepbound - Oncology medicines, including Verzenio - Immunology and neuroscience medicines - LillyDirect direct-to-patient access platform - Global commercialization and patient-support services ## Customers Lilly sells primarily to wholesalers, pharmacy benefit managers, insurers, plan sponsors, hospitals, government and long-term care institutions, and retail pharmacies, which then distribute medicines to patients. It also promotes directly to healthcare providers and, in the U.S., directly to consumers for selected products, reflecting a hybrid B2B and patient-access model. Demand is driven by chronic disease treatment, specialty prescribing, and payer coverage decisions. - **Wholesalers** (primary) — Large U.S. distributors purchase Lilly products for broad downstream supply to pharmacies, physicians, and hospitals. - **Payers and managed care organizations** (primary) — PBMs, insurers, plan sponsors, and managed care groups buy through rebates and formulary access decisions that determine utilization. - **Healthcare providers** (primary) — Physicians, hospitals, and clinics prescribe and administer specialty medicines such as oncology and diabetes therapies. - **Retail pharmacies** (secondary) — Pharmacies dispense branded medicines to patients and are important for chronic therapy fulfillment. - **Government and institutional buyers** (secondary) — Government agencies, long-term care institutions, and group purchasing organizations buy for covered populations and formularies. - **Patients** (emerging) — Patients access select medicines directly through LillyDirect and related support tools to improve adherence and convenience. - Wholesalers buy inventory for downstream pharmacy and provider distribution - PBMs and insurers negotiate rebates and access for covered patients - Physicians and hospitals prescribe specialty medicines to eligible patients - Retail pharmacies dispense products to end patients - Government and long-term care institutions purchase for covered populations - Patients use LillyDirect for access, delivery, and adherence support ## Geography Lilly manufactures and distributes products in the United States, including Puerto Rico, as well as in Europe and Asia, and sells in approximately 90 countries. The U.S. remains the most important market, but international growth is meaningful, especially as new launches expand outside the U.S. Geography matters because pricing, reimbursement, regulation, and supply-chain execution differ materially by market. - **United States** (68%) — Estimated from disclosures showing U.S. as the dominant market and product-level U.S. revenue disclosures. - **Outside United States** (32%) — Estimated from narrative disclosures; company reports outside-U.S. revenue as a combined region. - United States is the core market and the main source of branded demand - Outside the U.S. growth is driven by new market launches and volume expansion - Manufacturing is concentrated in the U.S., Europe, and Asia - Puerto Rico is part of the company’s manufacturing footprint - About 90 countries create broad regulatory and reimbursement exposure ## Strategy Lilly is prioritizing innovation-led growth through internal R&D, business development, and commercialization of differentiated medicines in large chronic disease markets. It is also expanding manufacturing capacity and digital access channels to meet demand and improve patient access, while using partnerships and licensing to broaden its pipeline and reach. These priorities support scale, supply reliability, and faster global rollout of new products. - **Expand manufacturing capacity** (short-term) — Demand for key medicines is rising faster than legacy supply networks, so capacity is central to growth and launch execution. - **Broaden patient access and commercialization channels** (short-term) — Direct-to-patient and digital tools can improve access, adherence, and brand reach while reducing friction in therapy initiation. - **Sustain pipeline innovation** (medium-term) — Long-term growth depends on replacing products that face competition or lose intellectual property protection. - **Expand internationally** (medium-term) — New markets diversify revenue and extend the lifecycle of major products beyond the U.S. - Invest in R&D and external innovation to replenish the pipeline - Scale manufacturing capacity to meet demand for current and future products - Expand LillyDirect and other patient-access channels - Grow internationally through new market launches and local partnerships - Use collaborations and licensing to accelerate commercialization ## Risks The main risk is pipeline and commercialization execution: Lilly must keep launching successful products fast enough to offset competition, patent loss, and changing treatment dynamics. It also faces manufacturing, quality, supply-chain, cyber, and regulatory risks because its products are complex to produce and distributed through a broad global network. Pricing pressure, rebates, and payer access decisions can materially affect realized revenue even when prescription demand is strong. - **Pipeline failure or weak commercialization** [high] — The company depends on new medicines and indications to replace revenue lost to competition and patent expiry. - **Manufacturing and supply-chain disruption** [high] — Complex biologic and specialty products require reliable production, third-party suppliers, and logistics. - **Cybersecurity and IT failure** [high] — LillyDirect, patient data, and global operations depend on secure systems and third-party service providers. - **Pricing and reimbursement pressure** [high] — Wholesalers, PBMs, insurers, and governments negotiate discounts and rebates that affect net sales. - **International competition and geopolitical exposure** [medium] — The company competes globally and relies on cross-border manufacturing, approvals, and market access. - R&D may fail to produce enough successful products to replace aging franchises - Manufacturing or supply disruptions can constrain product availability - Cybersecurity failures could disrupt operations or expose confidential data - Regulatory and compliance issues can delay launches or damage reputation - Payer rebates and pricing pressure can reduce realized revenue - Global competition, including China, is intensifying across therapeutic areas ## Accounting Key accounting issues for Lilly center on revenue recognition, rebates, and collaboration arrangements, because net product revenue depends on estimates for discounts, chargebacks, and returns. Investors should also watch milestone and royalty obligations, capitalized manufacturing investments, and impairment risk for acquired intangibles if product performance changes. Quarterly results can be affected by wholesaler buying patterns, foreign exchange, and launch timing across markets. - **Revenue deductions and reserves** — Affects reported revenue and gross margin - **Collaboration and other arrangements** — Affects top-line mix and operating income - **Milestone and royalty obligations** — Affects operating expenses and cash flow - **Capital expenditures and manufacturing assets** — Affects future margins and asset values - **Impairment of acquired intangibles** — Could create non-cash charges if forecasts weaken - Net product revenue depends on estimates for rebates, chargebacks, and returns - Collaboration and other revenue can create timing and classification complexity - Milestone and royalty payments affect expense timing and cash flow - Large manufacturing investments raise depreciation and capitalized asset risk - Acquired intangibles and goodwill may face impairment if product outlook weakens - Quarterly results can swing with wholesaler buying patterns and launch timing --- *Last updated: 2026-09-24T11:46:04.398960+00:00*